A detailed history of Advisor Group Holdings, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 5,456 shares of CSTL stock, worth $118,777. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,456
Previous 8,339 34.57%
Holding current value
$118,777
Previous $179,000 32.96%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$18.06 - $25.3 $52,066 - $72,939
-2,883 Reduced 34.57%
5,456 $120,000
Q4 2023

Feb 12, 2024

BUY
$12.19 - $22.43 $21,686 - $39,902
1,779 Added 27.12%
8,339 $179,000
Q3 2023

Nov 13, 2023

BUY
$13.28 - $20.3 $38,963 - $59,560
2,934 Added 80.92%
6,560 $110,000
Q2 2023

Aug 10, 2023

BUY
$11.66 - $26.0 $11,473 - $25,584
984 Added 37.24%
3,626 $49,000
Q1 2023

May 12, 2023

BUY
$19.47 - $28.49 $3,465 - $5,071
178 Added 7.22%
2,642 $60,000
Q4 2022

Feb 10, 2023

SELL
$18.08 - $30.0 $1,084 - $1,800
-60 Reduced 2.38%
2,464 $58,000
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $3,511 - $5,353
156 Added 6.59%
2,524 $65,000
Q2 2022

Aug 10, 2022

SELL
$16.0 - $45.99 $62,064 - $178,395
-3,879 Reduced 62.09%
2,368 $52,000
Q1 2022

May 04, 2022

SELL
$33.17 - $46.98 $10,614 - $15,033
-320 Reduced 4.87%
6,247 $279,000
Q3 2021

Nov 05, 2021

BUY
$60.13 - $77.6 $29,764 - $38,412
495 Added 8.15%
6,567 $437,000
Q2 2021

Aug 02, 2021

BUY
$50.07 - $76.78 $150,510 - $230,800
3,006 Added 98.04%
6,072 $444,000
Q1 2021

May 13, 2021

BUY
$58.92 - $97.33 $45,604 - $75,333
774 Added 33.77%
3,066 $210,000
Q4 2020

Feb 10, 2021

BUY
$43.6 - $73.05 $98,012 - $164,216
2,248 Added 5109.09%
2,292 $154,000
Q3 2020

Nov 12, 2020

BUY
$38.47 - $52.03 $1,615 - $2,185
42 Added 2100.0%
44 $2,000
Q1 2020

May 18, 2020

BUY
$23.08 - $35.53 $46 - $71
2 New
2 $0

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.